Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.62
JNJ's Cash to Debt is ranked lower than
55% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. JNJ: 1.62 )
Ranked among companies with meaningful Cash to Debt only.
JNJ' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 1.63 Max: 6.28
Current: 1.62
0.46
6.28
Equity to Asset 0.52
JNJ's Equity to Asset is ranked lower than
65% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. JNJ: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
JNJ' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.56 Max: 0.67
Current: 0.52
0.5
0.67
Interest Coverage 29.91
JNJ's Interest Coverage is ranked lower than
59% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 96.24 vs. JNJ: 29.91 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 36.85 Max: 208.73
Current: 29.91
28.29
208.73
F-Score: 7
Z-Score: 5.32
M-Score: -2.60
WACC vs ROIC
6.88%
28.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.71
JNJ's Operating margin (%) is ranked higher than
89% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. JNJ: 26.71 )
Ranked among companies with meaningful Operating margin (%) only.
JNJ' s Operating margin (%) Range Over the Past 10 Years
Min: 22.36  Med: 25.43 Max: 28.2
Current: 26.71
22.36
28.2
Net-margin (%) 20.97
JNJ's Net-margin (%) is ranked higher than
88% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.96 vs. JNJ: 20.97 )
Ranked among companies with meaningful Net-margin (%) only.
JNJ' s Net-margin (%) Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 21.99
Current: 20.97
14.87
21.99
ROE (%) 20.70
JNJ's ROE (%) is ranked higher than
84% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.03 vs. JNJ: 20.70 )
Ranked among companies with meaningful ROE (%) only.
JNJ' s ROE (%) Range Over the Past 10 Years
Min: 17.02  Med: 23.79 Max: 30.17
Current: 20.7
17.02
30.17
ROA (%) 11.01
JNJ's ROA (%) is ranked higher than
81% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. JNJ: 11.01 )
Ranked among companies with meaningful ROA (%) only.
JNJ' s ROA (%) Range Over the Past 10 Years
Min: 8.93  Med: 12.96 Max: 17.08
Current: 11.01
8.93
17.08
ROC (Joel Greenblatt) (%) 91.57
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.24 vs. JNJ: 91.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JNJ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 114.87
Current: 91.57
65.66
114.87
Revenue Growth (3Y)(%) 1.40
JNJ's Revenue Growth (3Y)(%) is ranked lower than
64% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. JNJ: 1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JNJ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 7.2 Max: 14.8
Current: 1.4
1.4
14.8
EBITDA Growth (3Y)(%) 9.30
JNJ's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.00 vs. JNJ: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JNJ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.6  Med: 10 Max: 16.7
Current: 9.3
-6.6
16.7
EPS Growth (3Y)(%) 12.40
JNJ's EPS Growth (3Y)(%) is ranked higher than
60% of the 520 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. JNJ: 12.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JNJ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 10.9 Max: 20.2
Current: 12.4
-8.6
20.2
» JNJ's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-13)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

JNJ Guru Trades in Q3 2015

Chuck Royce 9,000 sh (New)
Louis Moore Bacon 63,428 sh (New)
John Burbank 32,624 sh (New)
Charles Brandes 118,509 sh (New)
Jim Simons 392,000 sh (New)
Manning & Napier Advisors, Inc 4,406,762 sh (+33.86%)
Sarah Ketterer 1,593,359 sh (+31.91%)
RS Investment Management 10,457 sh (+21.90%)
Jeff Auxier 110,226 sh (+19.91%)
Pioneer Investments 2,381,190 sh (+15.13%)
John Rogers 884,154 sh (+13.06%)
Yacktman Focused Fund 2,600,000 sh (+4.00%)
Yacktman Fund 3,600,000 sh (+2.86%)
John Buckingham 64,896 sh (+2.30%)
Donald Yacktman 7,560,334 sh (+1.59%)
Tom Gayner 582,200 sh (+1.39%)
Murray Stahl 30,179 sh (+1.13%)
Mairs and Power 2,181,707 sh (+1.09%)
T Rowe Price Equity Income Fund 4,672,800 sh (+0.86%)
Mario Gabelli 317,847 sh (+0.86%)
Ken Fisher 10,689,483 sh (+0.45%)
Robert Olstein 71,000 sh (unchged)
John Hussman 1,325 sh (unchged)
Richard Perry 292,729 sh (unchged)
David Carlson 460,000 sh (unchged)
Richard Snow 3,270 sh (unchged)
Michael Price 25,000 sh (unchged)
Richard Pzena 1,174,169 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
David Dreman Sold Out
Ruane Cunniff 76,400 sh (-1.24%)
Barrow, Hanley, Mewhinney & Strauss 15,399,839 sh (-1.49%)
First Eagle Investment 1,585,928 sh (-1.50%)
Tweedy Browne 3,855,936 sh (-1.60%)
Dodge & Cox 36,935 sh (-3.40%)
PRIMECAP Management 10,575,867 sh (-6.99%)
Jeremy Grantham 11,529,743 sh (-10.67%)
Ray Dalio 167,593 sh (-14.05%)
Paul Tudor Jones 47,878 sh (-24.52%)
» More
Q4 2015

JNJ Guru Trades in Q4 2015

Joel Greenblatt 39,586 sh (New)
John Hussman 26,325 sh (+1886.79%)
John Burbank 68,755 sh (+110.75%)
First Eagle Investment 3,032,177 sh (+91.19%)
Jim Simons 655,300 sh (+67.17%)
Pioneer Investments 3,824,174 sh (+60.60%)
Charles Brandes 151,094 sh (+27.50%)
Mario Gabelli 332,287 sh (+4.54%)
Tom Gayner 605,200 sh (+3.95%)
John Buckingham 65,746 sh (+1.31%)
Ken Fisher 10,815,964 sh (+1.18%)
Mairs and Power 2,184,308 sh (+0.12%)
Richard Pzena 1,174,524 sh (+0.03%)
Richard Perry 292,729 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Robert Olstein 71,000 sh (unchged)
T Rowe Price Equity Income Fund 4,672,800 sh (unchged)
Michael Price 25,000 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Louis Moore Bacon Sold Out
PRIMECAP Management 10,543,562 sh (-0.31%)
Richard Snow 3,260 sh (-0.31%)
Barrow, Hanley, Mewhinney & Strauss 15,342,046 sh (-0.38%)
Murray Stahl 29,941 sh (-0.79%)
Paul Tudor Jones 46,483 sh (-2.91%)
Donald Yacktman 7,316,129 sh (-3.23%)
Yacktman Focused Fund 2,500,000 sh (-3.85%)
Dodge & Cox 35,435 sh (-4.06%)
Tweedy Browne 3,693,349 sh (-4.22%)
Jeff Auxier 105,426 sh (-4.35%)
John Rogers 831,664 sh (-5.94%)
Sarah Ketterer 1,497,289 sh (-6.03%)
RS Investment Management 9,592 sh (-8.27%)
Jeremy Grantham 9,970,431 sh (-13.52%)
Manning & Napier Advisors, Inc 3,769,800 sh (-14.45%)
Ruane Cunniff 64,753 sh (-15.24%)
Ray Dalio 109,693 sh (-34.55%)
» More
Q1 2016

JNJ Guru Trades in Q1 2016

Jim Chanos 29,730 sh (New)
Diamond Hill Capital 1,969 sh (New)
David Rolfe 5,250 sh (New)
John Burbank 1,583,456 sh (+2203.04%)
Joel Greenblatt 242,043 sh (+511.44%)
Jim Simons 2,380,600 sh (+263.28%)
Murray Stahl 30,774 sh (+2.78%)
John Rogers 850,915 sh (+2.31%)
Mario Gabelli 337,588 sh (+1.60%)
Tom Gayner 610,800 sh (+0.93%)
Richard Pzena 1,185,329 sh (+0.92%)
Ken Fisher 10,854,263 sh (+0.35%)
Mairs and Power 2,185,213 sh (+0.04%)
Chuck Royce 9,000 sh (unchged)
Richard Snow 3,260 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Jim Chanos 5,952 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Michael Price 25,000 sh (unchged)
Ray Dalio Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,327,465 sh (-0.10%)
Jeff Auxier 105,176 sh (-0.24%)
Dodge & Cox 34,808 sh (-1.77%)
Charles Brandes 146,253 sh (-3.20%)
John Buckingham 63,638 sh (-3.21%)
Donald Yacktman 7,080,500 sh (-3.22%)
Pioneer Investments 3,675,335 sh (-3.89%)
John Hussman 25,000 sh (-5.03%)
Manning & Napier Advisors, Inc 3,543,252 sh (-6.01%)
Yacktman Focused Fund 2,300,000 sh (-8.00%)
Tweedy Browne 3,383,445 sh (-8.39%)
Sarah Ketterer 1,364,323 sh (-8.88%)
Jeremy Grantham 9,036,395 sh (-9.37%)
RS Investment Management 8,397 sh (-12.46%)
T Rowe Price Equity Income Fund 3,961,300 sh (-15.23%)
Robert Olstein 50,000 sh (-29.58%)
First Eagle Investment 1,142,872 sh (-62.31%)
Paul Tudor Jones 15,876 sh (-65.85%)
PRIMECAP Management 3,023,678 sh (-71.32%)
Ruane Cunniff 13,925 sh (-78.50%)
» More
Q2 2016

JNJ Guru Trades in Q2 2016

Tom Russo 2,050 sh (New)
John Paulson 128,000 sh (New)
Louis Moore Bacon 3,552 sh (New)
Ray Dalio 129,700 sh (New)
Lee Ainslie 28,230 sh (New)
Jim Chanos 49,843 sh (+67.65%)
RS Investment Management 10,007 sh (+19.17%)
Jeremy Grantham 9,741,420 sh (+7.80%)
Diamond Hill Capital 2,110 sh (+7.16%)
Dodge & Cox 35,185 sh (+1.08%)
John Rogers 857,563 sh (+0.78%)
John Buckingham 63,881 sh (+0.38%)
Mairs and Power 2,185,819 sh (+0.03%)
Michael Price 25,000 sh (unchged)
John Hussman 25,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
David Carlson 460,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
David Rolfe 5,250 sh (unchged)
Warren Buffett 327,100 sh (unchged)
John Burbank Sold Out
Chuck Royce Sold Out
Jeff Auxier 105,126 sh (-0.05%)
Ken Fisher 10,845,150 sh (-0.08%)
Murray Stahl 30,622 sh (-0.49%)
Richard Snow 3,220 sh (-1.23%)
Paul Tudor Jones 15,553 sh (-2.03%)
Tweedy Browne 3,216,513 sh (-4.93%)
Donald Yacktman 6,671,349 sh (-5.78%)
PRIMECAP Management 2,830,937 sh (-6.37%)
Manning & Napier Advisors, Inc 3,297,804 sh (-6.93%)
Richard Pzena 1,103,032 sh (-6.94%)
Ruane Cunniff 12,933 sh (-7.12%)
Mario Gabelli 312,831 sh (-7.33%)
Charles Brandes 133,128 sh (-8.97%)
Pioneer Investments 3,223,857 sh (-12.28%)
Barrow, Hanley, Mewhinney & Strauss 13,210,591 sh (-13.81%)
T Rowe Price Equity Income Fund 3,400,000 sh (-14.17%)
Yacktman Focused Fund 1,950,000 sh (-15.22%)
Robert Olstein 41,000 sh (-18.00%)
First Eagle Investment 759,790 sh (-33.52%)
Sarah Ketterer 787,234 sh (-42.30%)
Jim Simons 626,100 sh (-73.70%)
Joel Greenblatt 4,906 sh (-97.97%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:PFE, NYSE:NVS, NYSE:MRK, NYSE:ABBV, OTCPK:GLAXF, NYSE:SNY, NYSE:BMY, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, OTCPK:SZUKF, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:PTKFF, OTCPK:SNPHY, OTCPK:MAYNF, NAS:GWPH » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. Baby Care includes the JOHNSON'S line of products. Oral Care includes the LISTERINE product line. Brands in Skin Care include the AVEENO; CLEAN & CLEAR; DABAO; JOHNSON'S Adult; LE PETITE MARSEILLAIS; LUBRIDERM; NEUTROGENA; and RoC product lines. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; and the PEPCID line of heartburn products. Brands in Women's Health outside of North America are STAYFREE and CAREFREE sanitary pads and o.b. tampon brands. Wound Care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious diseases and vaccines (e.g., HIV, hepatitis, respiratory infections and tuberculosis), neuroscience (e.g., Alzheimer's disease, mood disorders and schizophrenia), oncology (e.g., prostate cancer, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (e.g., thrombosis and diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis, and for adolescents with moderate to severe psoriasis; OLYSIO/SOVRIAD(simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA (darunavir), EDURANT (rilpivirine), and PREZCOBIX/REZOLSTA. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care

Guru Investment Theses on Johnson & Johnson

Yacktman Funds Comments on Johnson & Johnson - Aug 05, 2016

JNJ (NYSE:JNJ) performed well in the second quarter after delivering solid results. Few companies have the financial strength and product diversity of JNJ, which is why it is one of only two companies in the United States (Microsoft is the other) that commands a triple-A credit rating. We think JNJ can deliver solid growth and strong free cash flow over time.



From Yacktman Focused Fund (Trades, Portfolio) second quarter 2016 commentary.


Check out Donald Yacktman,Yacktman Focused Fund latest stock trades

Charles Brandes Comments on Johnson & Johnson - Oct 21, 2015

Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s.

From Charles Brandes (Trades, Portfolio)' third quarter 2015 commentary, Volatility: Misbehaving—In Action.

Check out Charles Brandes latest stock trades

Bill Frels Comments on Johnson & Johnson - Oct 20, 2014

Due to the expansion of its pharmaceutical business, Johnson & Johnson (JNJ) contributed better-than- expected performance during the period. Sales soared by 21% due to almost a dozen recent drug launches and improving profitability, which may support a robust acquisition strategy that could reportedly beat management’s goal of 4.5% growth in annual drug sales through 2017.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

Top Ranked Articles about Johnson & Johnson

Johnson & Johnson Is Currently Overvalued How Johnson & Johnson fares in the ModernGraham valuation model
Benjamin Graham taught that intelligent investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk. This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company, or by reviewing the 10 Companies Benjamin Graham Would Invest In Today - July 2016. By using the ModernGraham method, one can review a company's historical accomplishments and determine an intrinsic value that can be compared across industries. What follows is a stock analysis showing a specific look at how Johnson & Johnson (NYSE:JNJ) fares in the ModernGraham valuation model. Read more...
Ray Dalio's 5 Biggest 2nd-Quarter New Stock Buys Dalio bought Johnson & Johnson, CVS and more
Ray Dalio (Trades, Portfolio) manages the $150 billion Westport, Connecticut-based hedge fund Bridgewater Associates, the largest hedge fund firm in the world. The equity portfolio at Bridgewater has a total value of only $7.98 billion. According to filings disclosed Thursday, Dalio added 139 new positions to it in the second quarter. Read more...
Johnson & Johnson: Still a Steady Dividend Payout After 54 years of dividend growth, is it still ticking?
Johnson & Johnson (NYSE:JNJ) sits at the top of the healthcare sector with nearly $338 billion in market capitalization. That is more than a $100 billion higher valuation than pharma giant Pfizer. With more than $18 billion in operating income, JNJ is a cash flow generating machine that has withstood the test of time, increasing its dividends for the last 54 years. If you are a dividend hunter, you would have researched this company well before adding them to your portfolio. Read more...
Yacktman Funds Comments on Johnson & Johnson Guru stock highlight
JNJ (NYSE:JNJ) performed well in the second quarter after delivering solid results. Few companies have the financial strength and product diversity of JNJ, which is why it is one of only two companies in the United States (Microsoft is the other) that commands a triple-A credit rating. We think JNJ can deliver solid growth and strong free cash flow over time. Read more...
Johnson & Johnson: The Ultimate Buy, Hold Dividend Stock The company is the gold standard in dividend investing
With the stock market sitting near an all-time high, investors may be wondering if now is the right time to bail out of stocks. Read more...
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Pharmaceutical sales lead revenue higher for Johnson and Johnson
Johnson & Johnson (NYSE:JNJ) reported its second quarter 2016 earnings results on Tuesday, July 19. The company beat both revenue and earnings estimates for the quarter, helping to fuel continued momentum in U.S. stocks and the health care industry. For the quarter, revenue was $18.48 billion, beating analysts’ average estimate by $500 million. Revenue was also up 4% from the comparable quarter. Earnings for the second quarter were $1.74 beating analysts’ estimate by 6 cents. Read more...
T. Rowe Price Equity Income Fund Sells Apache, Johnson & Johnson in 2nd Quarter Largest sales by the guru firm of the last quarter
The following are his largest sells of the T. Rowe Price Equity Income Fund in the second quarter. Read more...
John Burbank's Best Investments Guru's acquisitions have been paying off
John Burbank (Trades, Portfolio) is the chief investment officer of Passport Capital LLC, the global investment firm he founded in 2000. He manages a portfolio composed of 98 stocks with total value of $6.101 billion. During the first quarter, the guru increased several stakes, and the following are the ones with the best performances since those buys. Read more...
Get Higher Returns and More Dividend Income – In Less Time With Less Risk The power and protection of valuation
Investing in blue-chip dividend growth stocks such as the Dividend Aristocrats or Champions has become very popular with retirees. This is understandable considering the low interest rate environment in which we find ourselves. Traditional fixed income investments do not currently offer enough yield for the retired investor to live on. Consequently, current low interest rates, coupled with the possibility of a steadily increasing level of dividend income have made dividend growth stocks a viable and even attractive alternative. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 22.44
JNJ's P/E(ttm) is ranked higher than
63% of the 533 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.83 vs. JNJ: 22.44 )
Ranked among companies with meaningful P/E(ttm) only.
JNJ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 24
Current: 22.44
10.5
24
Forward P/E 18.18
JNJ's Forward P/E is ranked lower than
54% of the 65 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.21 vs. JNJ: 18.18 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.44
JNJ's PE(NRI) is ranked higher than
62% of the 533 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.53 vs. JNJ: 22.44 )
Ranked among companies with meaningful PE(NRI) only.
JNJ' s PE(NRI) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 24
Current: 22.44
10.5
24
Price/Owner Earnings (ttm) 22.46
JNJ's Price/Owner Earnings (ttm) is ranked higher than
70% of the 278 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.03 vs. JNJ: 22.46 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JNJ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.19  Med: 17.56 Max: 25.26
Current: 22.46
10.19
25.26
P/B 4.51
JNJ's P/B is ranked lower than
69% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. JNJ: 4.51 )
Ranked among companies with meaningful P/B only.
JNJ' s P/B Range Over the Past 10 Years
Min: 2.68  Med: 3.72 Max: 5.26
Current: 4.51
2.68
5.26
P/S 4.73
JNJ's P/S is ranked lower than
67% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.72 vs. JNJ: 4.73 )
Ranked among companies with meaningful P/S only.
JNJ' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 3.23 Max: 4.95
Current: 4.73
2.17
4.95
PFCF 23.69
JNJ's PFCF is ranked lower than
51% of the 188 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.56 vs. JNJ: 23.69 )
Ranked among companies with meaningful PFCF only.
JNJ' s PFCF Range Over the Past 10 Years
Min: 10.28  Med: 16.55 Max: 24.84
Current: 23.69
10.28
24.84
POCF 18.95
JNJ's POCF is ranked lower than
57% of the 249 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.62 vs. JNJ: 18.95 )
Ranked among companies with meaningful POCF only.
JNJ' s POCF Range Over the Past 10 Years
Min: 8.98  Med: 13.22 Max: 19.85
Current: 18.95
8.98
19.85
EV-to-EBIT 16.62
JNJ's EV-to-EBIT is ranked higher than
64% of the 523 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.84 vs. JNJ: 16.62 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 12.9 Max: 18.2
Current: 16.62
7.8
18.2
EV-to-EBITDA 13.80
JNJ's EV-to-EBITDA is ranked higher than
63% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.38 vs. JNJ: 13.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.9 Max: 14.8
Current: 13.8
6.7
14.8
PEG 3.81
JNJ's PEG is ranked lower than
69% of the 287 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.99 vs. JNJ: 3.81 )
Ranked among companies with meaningful PEG only.
JNJ' s PEG Range Over the Past 10 Years
Min: 1.17  Med: 1.71 Max: 25.96
Current: 3.81
1.17
25.96
Shiller P/E 24.63
JNJ's Shiller P/E is ranked higher than
80% of the 154 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 51.85 vs. JNJ: 24.63 )
Ranked among companies with meaningful Shiller P/E only.
JNJ' s Shiller P/E Range Over the Past 10 Years
Min: 15.57  Med: 20.82 Max: 30.1
Current: 24.63
15.57
30.1
Current Ratio 3.08
JNJ's Current Ratio is ranked higher than
61% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. JNJ: 3.08 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.05 Max: 3.08
Current: 3.08
1.2
3.08
Quick Ratio 2.68
JNJ's Quick Ratio is ranked higher than
64% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. JNJ: 2.68 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.71 Max: 2.68
Current: 2.68
0.94
2.68
Days Inventory 139.66
JNJ's Days Inventory is ranked lower than
64% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. JNJ: 139.66 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 105.89 Max: 139.66
Current: 139.66
100.19
139.66
Days Sales Outstanding 62.12
JNJ's Days Sales Outstanding is ranked higher than
61% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.29 vs. JNJ: 62.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 62.12
Current: 62.12
53.94
62.12
Days Payable 102.60
JNJ's Days Payable is ranked higher than
70% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 67.61 vs. JNJ: 102.60 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 102.6
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.58
JNJ's Dividend Yield is ranked higher than
76% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. JNJ: 2.58 )
Ranked among companies with meaningful Dividend Yield only.
JNJ' s Dividend Yield Range Over the Past 10 Years
Min: 1.89  Med: 2.84 Max: 3.84
Current: 2.58
1.89
3.84
Dividend Payout 0.57
JNJ's Dividend Payout is ranked lower than
73% of the 373 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. JNJ: 0.57 )
Ranked among companies with meaningful Dividend Payout only.
JNJ' s Dividend Payout Range Over the Past 10 Years
Min: 0.29  Med: 0.42 Max: 6.33
Current: 0.57
0.29
6.33
Dividend Growth (3y) 7.10
JNJ's Dividend Growth (3y) is ranked lower than
51% of the 292 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. JNJ: 7.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
JNJ' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7  Med: 13 Max: 17.1
Current: 7.1
7
17.1
Forward Dividend Yield 2.69
JNJ's Forward Dividend Yield is ranked higher than
74% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 2.69 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.62
JNJ's Yield on cost (5-Year) is ranked higher than
74% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. JNJ: 3.62 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
JNJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.65  Med: 3.98 Max: 5.39
Current: 3.62
2.65
5.39
3-Year Average Share Buyback Ratio 0.10
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.60 vs. JNJ: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: -0.1 Max: 2.3
Current: 0.1
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.26
JNJ's Price/Tangible Book is ranked lower than
87% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. JNJ: 13.26 )
Ranked among companies with meaningful Price/Tangible Book only.
JNJ' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.24  Med: 10.42 Max: 18.92
Current: 13.26
6.24
18.92
Price/Projected FCF 1.71
JNJ's Price/Projected FCF is ranked higher than
65% of the 304 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. JNJ: 1.71 )
Ranked among companies with meaningful Price/Projected FCF only.
JNJ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.86  Med: 1.4 Max: 3.6
Current: 1.71
0.86
3.6
Price/DCF (Earnings Based) 2.10
JNJ's Price/DCF (Earnings Based) is ranked lower than
71% of the 78 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.39 vs. JNJ: 2.10 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.46
JNJ's Price/Median PS Value is ranked lower than
66% of the 653 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.15 vs. JNJ: 1.46 )
Ranked among companies with meaningful Price/Median PS Value only.
JNJ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.74  Med: 1.15 Max: 1.88
Current: 1.46
0.74
1.88
Price/Peter Lynch Fair Value 2.41
JNJ's Price/Peter Lynch Fair Value is ranked lower than
69% of the 155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. JNJ: 2.41 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JNJ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.2  Med: 1.87 Max: 4.03
Current: 2.41
1.2
4.03
Price/Graham Number 3.64
JNJ's Price/Graham Number is ranked lower than
71% of the 411 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.33 vs. JNJ: 3.64 )
Ranked among companies with meaningful Price/Graham Number only.
JNJ' s Price/Graham Number Range Over the Past 10 Years
Min: 1.97  Med: 3.16 Max: 5.97
Current: 3.64
1.97
5.97
Earnings Yield (Greenblatt) (%) 6.03
JNJ's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. JNJ: 6.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JNJ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.5  Med: 7.8 Max: 12.9
Current: 6.03
5.5
12.9
Forward Rate of Return (Yacktman) (%) 13.35
JNJ's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 330 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.82 vs. JNJ: 13.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JNJ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 14 Max: 18.6
Current: 13.35
1.8
18.6

More Statistics

Revenue (TTM) (Mil) $70,877
EPS (TTM) $ 5.32
Beta0.75
Short Percentage of Float0.84%
52-Week Range $81.79 - 126.07
Shares Outstanding (Mil)2,735.88

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 71,997 75,307 77,896
EPS ($) 6.60 7.11 7.39
EPS w/o NRI ($) 6.60 7.11 7.39
EPS Growth Rate
(3Y to 5Y Estimate)
3.80%
Dividends Per Share ($) 3.14 3.34 3.54
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
U.S. Stocks Trading Lower with Market Uncertainty Aug 22 2016 
US Stocks Higher after July FOMC Minutes Aug 17 2016 
Johnson & Johnson Is Currently Overvalued Aug 17 2016 
U.S. Market Indexes Lower on Tuesday Aug 16 2016 
Novartis Needs to Stem the Bleeding From Gleevec Decline Aug 16 2016 
Ray Dalio's 5 Biggest 2nd-Quarter New Stock Buys Aug 11 2016 
Ray Dalio's 5 Biggest 2nd-Quarter New Stock Buys Aug 11 2016 
Johnson & Johnson: Still a Steady Dividend Payout Aug 11 2016 
GlaxoSmithKline's Dividend Health Aug 09 2016 
Jeff Auxier's Summer 2016 Market Commentary Aug 05 2016 

More From Other Websites
7:00 am Johnson & Johnson and Genmab (GMXAY) submit Type II... Aug 23 2016
U.S. Stocks Trading Lower with Market Uncertainty Aug 22 2016
S&P 500, Dow industrials book a loss as oil snaps win streak Aug 22 2016
Apple, J&J Weigh on DJIA Monday Aug 22 2016
5 Stocks With Rising Dividends for 50 Years in a Row Aug 22 2016
McDonald's, Verizon And 3 Others That May Drag Down The Dow Aug 22 2016
For U.S. Media Only: Janssen Announces 25 Presentations at Upcoming ESC Congress 2016, Including New... Aug 22 2016
[$$] Two Strategies, One Crowded Trade Aug 21 2016
How Does Bristol-Myers Squibb’s Valuation Compare to Peers? Aug 19 2016
Hunting For Biotech Stocks? Understand The Earnings Formula First Aug 19 2016
Geron Shares Seen Range-Bound On Lack Of Major Data Until Late 2017 Aug 19 2016
Quality at a Low Cost Aug 19 2016
No Pain, Potential for Lots of Gain Aug 19 2016
ETF’s with exposure to Johnson & Johnson : August 18, 2016 Aug 18 2016
Pursche: A disconnect between fundamentals and valuations Aug 18 2016
Deutsche Takes A Look At Johnson & Johnson's Patent Woes Aug 18 2016
Recent Patent Ruling A Positive For Pfizer Aug 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)